Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2391262
Max Phase: Preclinical
Molecular Formula: C25H21N3O5S
Molecular Weight: 475.53
Molecule Type: Small molecule
Associated Items:
ID: ALA2391262
Max Phase: Preclinical
Molecular Formula: C25H21N3O5S
Molecular Weight: 475.53
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cccc(Cc2cc(-c3cccs3)nn(CC(=O)Nc3ccc4c(c3)OCO4)c2=O)c1
Standard InChI: InChI=1S/C25H21N3O5S/c1-31-19-5-2-4-16(11-19)10-17-12-20(23-6-3-9-34-23)27-28(25(17)30)14-24(29)26-18-7-8-21-22(13-18)33-15-32-21/h2-9,11-13H,10,14-15H2,1H3,(H,26,29)
Standard InChI Key: XYHVOCYINSAYHT-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 475.53 | Molecular Weight (Monoisotopic): 475.1202 | AlogP: 3.94 | #Rotatable Bonds: 7 |
Polar Surface Area: 91.68 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.69 | CX Basic pKa: | CX LogP: 3.85 | CX LogD: 3.85 |
Aromatic Rings: 4 | Heavy Atoms: 34 | QED Weighted: 0.44 | Np Likeness Score: -1.64 |
1. Giovannoni MP, Schepetkin IA, Cilibrizzi A, Crocetti L, Khlebnikov AI, Dahlgren C, Graziano A, Dal Piaz V, Kirpotina LN, Zerbinati S, Vergelli C, Quinn MT.. (2013) Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists., 64 [PMID:23685570] [10.1016/j.ejmech.2013.03.066] |
Source(1):